Eli Lilly And Company’s (NYSE:LLY) weight-loss drug, Zepbound (tirzepatide), is gaining traction in the U.S., rivaling Novo Nordisk A/S’s (NYSE:NVO) Wegovy (semaglutide). Due to ongoing supply issues, some doctors are prioritizing availability when prescribing these medications. Also Read: Using Weight Loss Medications Such As Wegovy, Zepbound? Psychologist Warns Of Linked Eating Disorder Risks. Reuters noted, citing IQVIA data, that Eli Lilly has captured roughly 40% of the market since Zepbound’s December launch. As of July 19, 130,000 prescriptions were filled weekly, compared to 200,000 for Wegovy. Five U.S. obesity specialists revealed they prescribe whichever drug is more accessible, sometimes requiring patients to switch treatments to maintain ...